Charles Swanton
| Use attributes for filter ! | |
| Gender | Male |
|---|---|
| Born | Poole |
| United Kingdom | |
| Doctoral advisor | Nic Jones |
| Field | Cancer |
| Date of Reg. | |
| Date of Upd. | |
| ID | 1076919 |
Charles Swanton Life story
Charles Swanton FRS FMedSci FRCP is British physician scientist specialising in oncology and cancer research.
At least 20,000 annual UK cancer deaths avoidable, says charity
... Prof Charles Swanton, who has been leading that study at the Francis Crick Institute, told BBC News the work could help doctors better predict how a patient s tumour will spread and how to fight it...
Study reveals cancer's ‘infinite' ability to evolve
... " That has never been done before at this scale, " said Prof Charles Swanton, from the Francis Crick Institute and University College London...
Air pollution cancer breakthrough will rewrite the rules
... One of the world s leading experts, Prof Charles Swanton, said the breakthrough marked a " new era"...
The scientists, a 'home-brew' coronavirus test
... Charles Swanton s days are busy, but the work is rewarding test...
Drug that prevents half of breast cancers carries on working
... Prof Charles Swanton, Cancer Research UK s chief clinician, said: Up until now we only knew that tamoxifen has long-lasting benefits, so it s reassuring that this study looking specifically at anastrozole, which has fewer long-term side-effects, gives better protection to women years after they stopped taking the drug...
Skin cancer: Half of people surviving advanced melanoma
... What do experts think? Prof Charles Swanton, chief clinician at Cancer Research UK, said the progress in melanoma had been incredibly fast ...
'Revolutionary' new class of cancer drugs approved
... Prof Charles Swanton, Cancer Research UK s chief clinician, said the drugs were exciting ...
'Revolutionary' new class of cancer drugs approved
Charlotte Stevenson was treated with a tumour-agnostic drug.
A "revolutionary" new class of cancer drug that can treat a wide range of tumours has been approved for use in Europe for the First Time .
Tumour-agnostic drugs do not care where the cancer is growing in The Body as long as it has a specific genetic abnormality inside.
UK doctors testing the drugs said they were "a really exciting thing".
They said the approach had the potential to cure more patients and cut side-effects.
The drug that has been approved is called larotrectinib.
Charlotte Stevenson, a two-year-old from Belfast, was one of The First patients to benefit.
She was diagnosed with infantile fibrosarcoma, a cancer of The Body 's connective tissue.
She has been treated with larotrectinib as part of a clinical trial at The Royal Marsden Sutton, in London, for The Past year.
Her mum, Esther, said: "We knew that our options were limited [so] we decided to give it a try and are so glad that we did.
"We have been able to watch Charlotte develop and grow at a rapid rate, Making Up for Lost Time in so many ways and amazing us all with her energy and enthusiasm For Life .
"She can now have a relatively normal life and, best of all, the drug has had an incredible impact on the tumour. "
Charlotte's tumour was caused by a genetic abnormality known as an NTRK gene fusion.
One part of her DNA accidentally merged with another and The Alteration in The Blueprint for her body led to the growth of her cancer.
But NTRK gene fusions are not unique to sarcomas - they also appear in some brain, kidney, thyroid and other cancers.
"It is a really exciting thing, As Is it works across a range of cancers. It's not confined to one," Dr Julia Chisholm, a children's cancer consultant at The Royal Marsden Hospital, told the BBC.
NTRK mutations are relatively rare, but other targeted therapies are in development.
'Kinder treatments'It marks a Move Away from treating a "breast cancer" or "bowel cancer" or a "lung cancer" and towards precision medicine that takes advantage of the genetic make-up of each patient's tumour.
Dr Chisholm told the BBC: "The beauty is it targets the abnormality.
"There are A Number of biochemical pathways that are common in many different tumour types.
"I think this is the way things are going and this is about better outcomes, curing more patients and producing kinder treatments with reduced side-effects. "
The decision by European regulators does not mean it will be instantly available for patients in the UK.
But earlier this year, tumour-agnostic drugs as a "revolutionary" and "exciting new breakthrough" in cancer and said preparations were under way to ensure patients were given access to them.
"The benefits for patients - in particular children - of being able to treat many different types of cancers with one drug is potentially huge, helping them to lead longer, healthier lives," Nhs England chief executive Simon Stevens said at the time.
Prof Charles Swanton , Cancer Research UK's chief clinician, said the drugs were "exciting".
He added: "The NHS will need to ensure The Right genomic testing is available across the country to identify patients who could benefit so it's good that the NHS is already thinking about How To get this to patients with cancer as soon as possible. "
Dr Brendon Gray, from Bayer, the drug company that developed larotrectinib, said: "As The First tumour-agnostic medicine approved in Europe, larotrectinib represents a real shift in cancer treatment. "
cancer, medical research
Source of news: bbc.com
Charles Swanton Photos
